With the Affordable Care Act, healthcare is rapidly moving towards a new market paradigm in which the consumer is the primary economic decision maker. Payers and providers will likely spend more on new information tools focused on the healthcare consumer and driving efficiency. Biopharma and medtech companies can drive higher valuations with innovative products that deliver both better clinical outcomes and cost reduction for the industry.
ICR has partnered with more than 75 biopharma, medtech, diagnostics, services and HCIT companies. Our dedicated healthcare team includes professionals with experience as buy-side analysts, sell-side analysts, and investment bankers with direct responsibility for over $15 billion in capital markets healthcare transactions. With our extensive network of healthcare equity research analysts, institutional investors, venture capitalists and bankers, your message carries the credibility to get a favorable reception. Leveraging our healthcare industry knowledge and strategic communications expertise, we invest the resources to understand each client’s business model and competitive differentiation in order to provide strategic counsel and unmatched execution on both a pre-IPO and post-IPO basis or in raising the company’s visibility and preparing for a strategic sale.